Tenders Are Invited For Pharmaceutical Products – Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Omalizumab (Atc Code: R03dx05).

Pharmaceutical Products – Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Medicines With The Active Ingredient Omalizumab (Atc Code: R03dx05).. The Aok Lower Saxony. Until Exclusive Contracts Come Into Force After A Public Tender In Accordance With The Regulations Of Part 4 Of The Gwb, The Health Insurance Fund Intends To Conclude Non-Exclusive Drug Discount Contracts For The Active Ingredient Omalizumab (Atc Code: R03dx05) With As Many Market Participants As Possible (Pharmaceutical Companies Or Communities Of Pharmaceutical Companies) In The So-Called . To Complete The “Open-House Model”. Aok Niedersachsen Will Not Make A Selection Decision And Will Make An Identical Contract Offer To Every Interested Pharmaceutical Company. In The Open-House Model, Uniform Conditions Apply To All Participants. Contract Contents, Conditions And Access Procedures Are Uniform - Individual Negotiations Are Generally Not Carried Out. The Contract Terms Are A Maximum Of Twenty-Four Months; The Earliest Contract Start Date Is December 1St, 2024. All Contracts End On November 30, 2026 At The Latest, Regardless Of The Date Of Conclusion Of The Respective Contract. Joining Or Concluding A Contract Can Take Place On The First Of Each Month Within The Twenty-Four Month Period. There Is A Right Of Termination Six Weeks To The End Of The Month. Aok Niedersachsen Reserves The Right To Replace The Non-Exclusive Open-House Discount Agreements With Exclusive Discount Agreements During The Contract Term. When Advertised, Exclusive Discount Contracts Come Into Force, The Open-House Contracts Will Be Terminated In Accordance With The Contractual Regulations, I.E. H. The Open-House Contracts End Automatically. According To Aok Niedersachsens Experience, Exclusive Discount Agreements Usually Come Into Force Six To Eight Months After The Publication Of The Corresponding Tender Notice In The Supplement To The Official Journal Of The European Union. The Future Contractual Partners In The Open-House Model Are Requested To Regularly Consult The Supplement To The Official Journal Of The European Union Regarding These Tender Notices. Interested Pharmaceutical Companies Can Request The Contract Documents And The Contract Conditions At The Contact Address Given Under I.1). Contracts For The Active Ingredient Omalizumab (Atc Code: R03dx05) Will Be Concluded For The First Time With Effect From December 1, 2024. Interested Parties Who Would Like To Become Contractual Partners On This Date Must Submit The Contract Documents To Be Submitted By October 28, 2024 To The Address Specified In The Contract Documents. It Depends On Access To Aok Niedersachsen. Later Contract Conclusions Are Possible On The First Of Each Month During The Twenty-Four-Month Maximum Term. From An Organizational Point Of View, The Aok Generally Needs A Lead Time Of 35 Calendar Days To Carry Out The Necessary Work, E.G. B. To Be Able To Ensure Contract Reporting In The Lauer-Taxe®. The Exact Deadlines For Receipt Will Be Announced With The Contract Documents. This Publication Is About